Aflac Inc. reported second-quarter 2026 revenue of USD 4.22 billion, beating the consensus estimate of USD 4.11 billion. However, earnings per share came in at USD 1.75, slightly missing the USD 1.76 expected by analysts and falling below the prior year's comparable period of USD 1.78. Revenue declined by 1.00 percent from the previous year, indicating a slight contraction in top-line growth despite the beat on consensus estimates. Following the earnings release, analyst sentiment regarding Aflac's valuation has diverged significantly. Wells Fargo cut its price target for the insurer from USD 122.00 to USD 116.00 on October 12, 2026, citing the mixed performance metrics. Conversely, other analysts like Jefferies and Piper Sandler have maintained or raised their targets, creating a split view within the analyst community regarding the stock's immediate valuation. The wider analyst consensus remains measured with fourteen analysts carrying a Hold rating and an average 12-month price target of USD 115.31. Aflac shares were trading around USD 115.89 on October 12, 2026, within a 52-week range of USD 105.43 to USD 130.22. The company is scheduled to release its third-quarter 2026 results on November 4, 2026, providing investors with another opportunity to assess the trajectory of revenue and earnings. The market capitalization stands at approximately USD 59.0 billion as of October 12, 2026. Investors are closely watching whether future quarters can narrow the gap between operating figures and competing analyst targets, particularly given the recent divergence in price target adjustments from major financial institutions covering the stock.